Neurocrine Biosciences (NBIX) Market Capitalization (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Market Capitalization for 17 consecutive years, with $17.1 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Market Capitalization rose 37.61% year-over-year to $17.1 billion; the trailing twelve-month figure through Jun 2026 stood at $17.1 billion (up 37.61% YoY), and the FY2025 full-year result was $14.2 billion, up 4.64% from the prior year.
• Market Capitalization improved to $17.1 billion in Q2 2026 per NBIX's latest filing, from $13.3 billion in the prior quarter.
• Across five years, Market Capitalization topped out at $17.1 billion in Q2 2026 and bottomed at $9.0 billion in Q1 2022.
• Historically, Market Capitalization has averaged $12.1 billion across 5 years, with a median of $12.1 billion in 2024.
• The sharpest annual moves came in 2024 and 2025: Market Capitalization soared 50.93% in 2024, then fell 21.08% in 2025.
• Over 5 years, Market Capitalization stood at $11.5 billion in 2022, then grew by 12.83% to $13.0 billion in 2023, then gained by 4.33% to $13.6 billion in 2024, then gained by 4.64% to $14.2 billion in 2025, then grew by 20.61% to $17.1 billion in 2026.
• According to Business Quant data, Market Capitalization over the past three periods registered $17.1 billion, $13.3 billion, and $14.2 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.